Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

This study has been completed.

Study NCT00068315 Information provided by Case Comprehensive Cancer Center

First Received: September 10, 2003 Last Updated: June 10, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	March 2010
Primary Completion Date:	October 2008 (Final data collection date for primary outcome measure)

Publications:

Barr PM, Fu P, Lazarus HM, Horvath N, Gerson SL, Koc ON, Bahlis NJ, Snell MR, Dowlati A, Cooper BW. Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. Br J Haematol. 2009 Oct;147(1):89-96. Epub 2009 Jun 29.

Snell M, Koc ON, Bahlis NJ, et al.: A phase I trial of PS-341 and fludarabine for relapsed and refractory indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. [Abstract] J Clin Oncol 24 (Suppl 18): A-7580, 441s, 2006.

Koc ON, Bahlis NJ, Liu L, et al.: A phase I trial of bortezomib in combination with fludarabine in patients with lymphoproliferative neoplasms. [Abstract] J Clin Oncol 23 (Suppl 16): A-6647, 596s, 2005.